Is your patient taking infliximab or another anti–tumor necrosis factor therapy for treatment of rheumatoid arthritis (RA)? Use of these agents places the patient at an increased risk for infection—in some cases, life-threatening. Any signs or symptoms of infection in the patient with RA warrant immediate evaluation, and blood cultures should be included for early identification of the causative organism,appropriate treatment, and increased chances of a positive outcome.